Laxxon Medical accelerates commercialization through strategic partnership with Hovione

Laxxon Medical has partnered with family-owned international pharmaceutical contract manufacturer Hovione to produce the first 3D screen printed clinical samples of tablets on an industrial scale and under cGMP standards. This major step towards commercialization is thanks to a strategic partnership with Hovione, that has been a reliable partner for the pharmaceutical industry for decades and has an excellent reputation for innovation and best practice. Hovione has four FDA-cleared manufacturing sites as well as development laboratories in Lisbon, Portugal and New Jersey, USA. Laxxon Medical and Hovione plan to work together to advance the use of 3D screen printing technologies in the pharmaceutical industry. The partnership will make the 3D screen printing platform available from early development stages to routine commercial manufacturing. Under the agreement, Hovione will introduce Laxxon Medical's 3D screen printing technology, SPID®-Technology, to Hovione's cGMP manufacturing facilities, initially in Portugal and later in the United States.

The partnership combines Laxxon's expertise in 3D screen printing, based on SPID®-Technology, with Hovione's product and process development, engineering and manufacturing expertise in pharmaceutical applications. Laxxon’s 3D screen printing technology has numerous advantages, including the potential to produce unique or customized dosage forms with properties that cannot be achieved with conventional dosage forms, including the ability to produce tablets of any shape and size, the ability to easily customize the number of active ingredients and individual components in the tablet's composition, and even to customize the dosage for each patient to produce personalized medicines.

Klaus Kühne, COO of Laxxon Medical commented, "Laxxon is pleased to enter into a long-term partnership with Hovione. This partnership will significantly accelerate the establishment of 3D screen printing in the pharmaceutical industry and thus our ability to serve our customers."

Helmut Kerschbaumer, CEO of Laxxon added, "Hovione has a global reputation for its pharmaceutical innovation services, expertise and market access. This agreement is a significant milestone for Laxxon in terms of our own market strategy and development efforts."

Dr. Jean-Luc Herbeaux, CEO of Hovione stated, "We consider Laxxon Medical's 3D printing technology very innovative and promising. Not only does it enable the customization and manufacture of drugs with complex shapes and structures and unique drug release properties, but it also has the potential to reduce the time and cost of drug development. We are excited about the prospect of helping Laxxon industrialize its 3D printing technology and make it available to a wider range of pharmaceutical and medical device companies."

About Laxxon Medical
Laxxon Medical is a pharmaceutical technology company that develops patented, state-of-the-art 3D screen printing development and manufacturing solutions for the pharmaceutical industry. Laxxon's SPID® (Screen Printing Innovational Drug) Technology enables different pharmaceutical application forms such as oral, transdermal and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients that enable different release profiles such as sequential release. SPID® Technology can be used to print small batches for research and development to commercial scale production without changing the manufacturing process.

SPID®-Technology (3D screen printing)
Screen Printed Innovative Drug Technology (SPID®) is an additive manufacturing process that enables the development and production of complex formulations and geometric structures of oral dosage forms to optimize the release profiles of current drugs and new drug developments.

About Hovione
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing. As a Contract Development and Manufacturing Organization (CDMO), the company offers a fully integrated range of services for APIs, intermediates and drugs. The company has four FDA-cleared sites in the U.S., Portugal, Ireland and China, as well as development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers with services for the development and compliant manufacturing of innovative medicines, including highly potent compounds, as well as customized product solutions for the entire drug lifecycle. In the inhalation field, Hovione offers a full range of services, from compound and formulation development to devices. Hovione's corporate culture is based on innovation, quality and reliability. Hovione was the first chemical-pharmaceutical company to be certified as a B Corp, is a member of Rx-360 and EFCG, and actively participates in industry quality improvement initiatives to set new global industry standards.

Disclaimer: GOLDINVEST Consulting GmbH offers editors, agencies and companies the possibility to publish comments, analyses and news on https://www.goldinvest.de. These contents serve exclusively the information of the readers and do not represent any kind of call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they in no way replace an individual expert investment advice, it is rather promotional / journalistic publications. Readers who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. The acquisition of securities, especially with shares in the penny stock area, carries high risks, which can lead to a total loss of the invested capital. The GOLDINVEST Consulting GmbH and its authors exclude any liability for financial losses or the content guarantee for topicality, correctness, adequacy and completeness of the articles offered here expressly. Please also note our terms of use.

According to §34b WpHG and according to paragraph 48f paragraph 5 BörseG (Austria) we would like to point out that principals, partners, authors and employees of GOLDINVEST Consulting GmbH hold or may hold shares of Laxxon Medical Corp. and therefore a possible conflict of interest exists. We also cannot exclude that other stock letters, media or research firms discuss the stocks we recommend during the same period. Therefore, symmetrical information and opinion generation may occur during this period. Furthermore, there is the prospect of a consulting or other service contract between Laxxon Medical Corp. and GOLDINVEST Consulting GmbH, which means that a conflict of interest exists.